OYX — Bcr/Abl1 Monitoring Test Class II

FDA Device Classification

Classification Details

Product Code
OYX
Device Class
Class II
Regulation Number
866.6060
Submission Type
Review Panel
PA
Medical Specialty
Medical Genetics
Implant
No

Definition

A BCR/ABL1 Monitoring Test is a quantitative in vitro diagnostic device used to monitor the BCR/ABL1 to ABL1 ratio by reverse-transcriptase quantitative polymerase chain reaction (RQ-PCR) on whole blood or bone marrow of diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) patients expressing BCR-ABL1 fusion transcripts such as e13a2 and/or e14a2. It is intended for use during monitoring of treatment response by reporting results on the international scale (%IS) and as log molecular reduction (MR) value.

Recent 510(k) Clearances

K-NumberApplicantDevice NameDate
K221869suzhou sniper medical technologies coBCR-ABL1 (p210) % IS Kit (Digital PCR Method)September 5, 2023
K190076cepheidXpert BCR-ABL Ultra, GeneXpert Dx System, GeneXpert Infinity-48s and GeneXpert ISeptember 27, 2019
K181661bio-rad laboratoriesQXDx BCR-ABL %IS Kit for use on the QXDx AutoDG ddPCR SystemFebruary 13, 2019
K173492molecularmd corporationMRDx BCR-ABL Test, MRDx BCR-ABL Test SoftwareDecember 22, 2017
DEN160003asuragenQuantidex qPCR BCR-ABL IS KitJuly 22, 2016